

Evidence for the Importance of High-Valent Fe=O and of a Diketone in the Molecular Mechanism of Action of Antimalarial Trioxane Analogs of Artemisinin

Gary H. Posner,^{*,†} Sheldon B. Park,[†] Lluïsa González,[†] Dasong Wang,[†] Jared N. Cumming,^{†,‡} Donna Klinedinst,[§] Theresa A. Shapiro,[§] and Mario D. Bachi^{||}

Department of Chemistry, School of Arts and Sciences, The Johns Hopkins University
Baltimore, Maryland 21218

Department of Medicine, School of Medicine
The Johns Hopkins University
Baltimore, Maryland 21205

Department of Organic Chemistry
The Weizmann Institute of Science, Rehovot, Israel

Received December 8, 1995

Ancient Chinese folk medicine has led relatively recently to chemical identification of the 1,2,4-trioxane sesquiterpene artemisinin (qinghaosu, **1**), representing a new class of fast-acting, clinically useful, antimalarial drugs.^{1,2} This natural endoperoxide and some related synthetic organic endoperoxides, causing oxidative stress to malaria parasites,³ are reduced by the iron-rich parasites to form cytotoxic radical intermediates.⁴ We have designed and synthesized some structurally simplified 1,2,4-trioxanes to determine whether they are reduced by ferrous iron to form the same kinds of radical intermediates as formed upon iron(II) reduction of artemisinin.^{5,6} The simplified trioxanes we report here were formulated such that an intermediate carbon-centered radical would be intercepted before β -scission of Fe(III)–O $\cdot$ [$\leftrightarrow$ Fe(IV)=O] either by a competing β -scission of a better radical leaving group X $\cdot$ from radical intermediate **2a** (Scheme 1A) or by a competing subsequent 1,5-hydrogen atom shift in radical intermediate **3a** (Scheme 1B); such mechanistically competing reactions were expected to interrupt formation of a high-valent iron–oxo species and thus to diminish or to undermine completely the antimalarial activity of these artemisinin analogs. Also, another analog was designed to have improved and therefore medicinally more desirable antimalarial potency by incorporating a structural feature that would facilitate β -scission of a high-valent iron–oxo species. We report here *in vitro* antimalarial activities that support the intermediacy of such high-valent iron–oxo species *via* the β -scission pathway in the antimalarial artemisinin analogs shown in Table 1. We report evidence also of a simple diketone as an unexpectedly antimalarial product formed upon iron(II) reduction of a trioxane.

Scheme 1




Table 1. Chemical Structure–Antimalarial Activity Relationships in Chloroquine-Sensitive *Plasmodium falciparum* (NF54) Parasites *In Vitro*^a

trioxane	X	R	IC ₅₀	
			ng/mL	nM
4	Ph	CH ₂ CH ₂ OH	3.0	8.3
5	Me ₃ Si	CH ₂ CH ₂ OH	86	240
6	Me ₃ Sn	CH ₂ CH ₂ OH	>1000	>2500
7	Ph	H	98	340
8	Me ₃ Sn	H	>1000	>2500
10		Me	220	960
11		Et	170	710
12		(CH ₃) ₂ CHCH ₂ CH ₂	46	160
13		PhCH ₂ CH ₂ CH ₂	35	110
14		CH ₂ =CH	11	46
15		Ph	11	38
artemisinin (1)			3.0	11
arteether			1.9	6.1
chloroquine			2.6	5.0

^a Antimalarial activity was determined as reported previously.⁵ The standard deviation for each set of quadruplicates was $\leq 45\%$ of the mean. R^2 values for the curves were ≥ 0.993 .

Trioxanes **5** and **6** differ by only one atom: silicon *vs* tin. Despite this small structural difference within a complex organic endoperoxide, C₄ β -silyl analog **5** has significant antimalarial activity, whereas tin analog **6** is virtually inactive (Table 1). Likewise, 8a-unsubstituted C₄ β -stannyl analog **8** has virtually no antimalarial activity, whereas similar C₄ β -substituted analog **7** is active. These results are consistent with selective β -scission of Me₃Sn $\cdot$ [rather than Fe(III)–O $\cdot$] from the intermediate C₄-carbon radical **2a** (X = Me₃Sn, Scheme 1A). Also, the absence (<0.1%) of hexamethyl Dewar benzene (HMDB) rearrangement during FeBr₂ reduction of C₄ β -stannyl trioxane **8** is consistent with the absence of a high-valent iron–oxo intermediate.⁶ As a control to show that the presence of a tin atom does not necessarily destroy a trioxane's antimalarial activity, tin-containing dihydroartemisinin analog **9** was synthesized⁷ and was found to have measurable *in vitro* antimalarial activity (IC₅₀ = 750 ng/mL, 1300 nM).

(7) All new compounds were fully characterized spectroscopically and by HRMS and/or combustion analysis.

[†] Department of Chemistry, The Johns Hopkins University.

[‡] Recipient of a Graduate Fellowship from the Organic Chemistry Division of the American Chemical Society (1995–1996) sponsored by Abbott Laboratories.

[§] Department of Medicine, The Johns Hopkins University.

^{||} The Weizmann Institute of Science.

(1) For reviews, see: (a) Klayman, D. L. *Science* **1985**, 228, 1049. (b) White, N. J. *Trans. R. Soc. Trop. Med. Hyg.* **1994**, 88 (Suppl. 1), 1. (c) Zhou, W.-S.; Xu, X.-X. *Acc. Chem. Res.* **1994**, 27, 211. (d) Jung, M. *Curr. Med. Chem.* **1994**, 1, 45. (e) Meshnick, S. R.; Taylor, T. E.; Kamchonwongpaisan, S. *Microbiol. Rev.*, in press. (f) Cumming, J. N.; Ploypradith, P.; Posner, G. H. *Adv. Pharmacol.* **1996**, 37.


(2) Avery, M. A.; Gao, F.; Chong, W. K. M.; Hendrickson, T. F.; Inman, W. D.; Crews, P. *Tetrahedron* **1994**, 50, 957 and references therein.

(3) *Free Radicals in Tropical Diseases*; Aruoma, O. I., Ed.; Harwood Academic: Chur, Switzerland, 1993.


(4) (a) Meshnick, S. R.; Yang, Y.-Z.; Lima, V.; Kuypers, F.; Kamchonwongpaisan, S.; Yuthavong, Y. *Antimicrob. Agents Chemother.* **1993**, 37, 1108. (c) Hong, Y.-L.; Yang, Y.-Z.; Meshnick, S. R. *Mol. Biochem. Parasitol.* **1994**, 63, 121.

(5) Posner, G. H.; Wang, D.; Cumming, J. N.; Oh, C. H.; French, A. N.; Bodley, A. L.; Shapiro, T. A. *J. Med. Chem.* **1995**, 38, 2273. See also: Bloodworth, A. J.; Shah, A. *Tetrahedron Lett.* **1995**, 36, 7551.

(6) Posner, G. H.; Cumming, J. N.; Ploypradith, P.; Oh, C. H. *J. Am. Chem. Soc.* **1995**, 117, 5885.




Further experimental support for these mechanistic conclusions comes from the ferrous bromide induced transformation of $C_4\beta$ -stannyl analog **8** into two major non-tin-containing olefinic products (eq 1). Although formation of non-tin-containing terminal olefin **8b** might result from a concerted radical fragmentation⁸ initiated by electron donation from Fe(II) to oxygen-1 in trioxane **8**, formation of exocyclic olefin **8a**, isolated in 15% yield, must arise from β -scission of $Me_3Sn^{\bullet}$ from its C_4 -radical precursor.⁹ Thus, at least 15% of the Fe(II) reduction of trioxane **8** proceeds *via* the antimalarial crucial pathway involving C_4 -radical **2a** (Scheme 1A).¹⁰



C_3 -substituted analogs **12** and **13**, in which a 1,5-hydrogen atom shift from the secondary C_4 -radical intermediate **3a** (Scheme 1B) could occur to form tertiary radical **3b** (from analog **12**) or even considerably more stable¹¹ secondary benzylic radical **3b** (from analog **13**), both have comparable and considerable antimalarial activity. Thus, competing subsequent 1,5-hydrogen atom shifts¹² apparently are not fast enough to intercept the key C_4 -radical intermediates before β -scission of $Fe(III)-O^{\bullet}$ can occur. The antimalarial activities of analogs **12** and **13**, being much higher than those of C_3 -methyl and C_3 -ethyl analogs¹³ **10** and **11** in which no subsequent 1,5-H shift is possible (Table 1), may be due to the higher lipophilicity of analogs **12** and **13** and therefore possibly also to their better transport in biological systems. Both C_3 -substituted analogs **12** and **13** react with ferrous bromide and excess HMDB in THF to form hexamethylbenzene, a rearrangement characteristic of a high-valent iron-oxo intermediate.⁶ In a control reaction, HMDB in THF was not rearranged when $(t-BuO)_2$ was reduced by $FeBr_2$.

To facilitate β -scission of $Fe(III)-O^{\bullet}$ from the C_4 -radical intermediate, leading to formation of a C_3-C_4 carbon-carbon double bond,^{9b} a structural feature that would stabilize such a new olefinic bond was incorporated. C_3 -vinyl analog **14**,⁷ in which the new olefinic bond can be stabilized by conjugation with the unsaturated C_3 -substituent, is considerably more antimalarially active than the corresponding C_3 -ethyl analog **11**.^{13b} Ferrous bromide induced reduction of peroxide **14** causes rearrangement of HMDB into hexamethylbenzene.⁶ Although

3-phenyltrioxane **15**¹³ also has high antimalarial activity, its reduction by $FeBr_2$ unexpectedly does not generate high-valent $Fe=O$ (*i.e.*, no rearrangement of HMDB) but does generate an antimalarial product (diketone **17**). The two major products of $FeBr_2$ reduction of 3-phenyltrioxane **15** are ring-contracted tetrahydrofuran **16** and 1,5-diketone **17**, formed plausibly *via* electron transfer to oxygen-1 of trioxane **15** (eq 2).⁷ Because some dicarbonyl compounds are known to alkylate proteins,¹⁴ as does artemisinin,¹⁵ the *in vitro* antimalarial activity of 1,5-diketone **17** was determined ($IC_{50} = 330$ ng/mL, 1400 nM). This is the first time that any diketone has been reported to have antimalarial activity;¹⁶ the low antimalarial activity of diketone **17** may be due to its relative difficulty in reaching the malaria parasite inside the red blood cell. Thus, phenyltrioxane **15** may be acting in part as a prodrug for release of 1,5-diketone **17** inside the malaria parasite.^{1f}



In conclusion, the results summarized in eq 1 show that when a group like Me_3Sn , being a better radical leaving group⁹ than $Fe(III)-O^{\bullet}$, is situated as in trioxane **8**, then generation of $Fe(III)-O^{\bullet}$ is precluded (*cf.* Scheme 1A). The absence of antimalarial activity of tin-containing compounds **6** and **8**, in contrast to the considerable antimalarial activity of structurally similar compounds **4**, **5**, and **7**, provides the first evidence supporting the central role of a biologically relevant¹⁷ high-valent iron-oxo species in the mode of action of antimalarial analogs of the natural trioxane artemisinin.⁶ Also, the first example is provided of any 1,5-diketone having antimalarial activity.^{18,19}

Acknowledgment. We thank the NIH (grants AI-34885 and NCRR, OPD-GCRC RR00722) and the Burroughs Wellcome Fund for financial support, the Canadian Government for an NSERC postdoctoral fellowship to S.B.P., the Generalitat de Catalunya for a postdoctoral fellowship to L.G., and the Hopkins-Weizmann Exchange Program for support of Mario D. Bachi during a stay in Baltimore in 1994.

Supporting Information Available: Spectra of **6**, **8**, **8a**, **8b**, **9**, **12–14**, **16**, and **17** (20 pages). This material is contained in many libraries on microfiche, immediately follows this article in the microfilm version of the journal, can be ordered from the ACS, and can be downloaded from the Internet; see any current masthead page for ordering information and Internet access instructions.

JA954131P

(8) Curran, D. P.; van Elburg, P. A.; Giese, B.; Gilges, S. *Tetrahedron Lett.* **1990**, 31, 2861. These mechanistic details are being investigated further, and results will be reported in a full paper in due course.

(9) (a) Kochi, J. K. *J. Am. Chem. Soc.* **1962**, 84, 1193. (b) Motherwell, W. B.; Crich, D. *Free Radical Chain Reactions in Organic Synthesis*; Academic: New York, 1992; Chapter 4. (c) Davies, A. G.; Roberts, B. P.; Tse, M.-W. *J. Chem. Soc., Perkin Trans. 2* **1978**, 145.

(10) For example, $FeBr_2$ -induced reduction of the potent antimalarial artemisinin leads to only 10–15% of its C_4 -hydroxylated product *via* the crucial C_4 -radical intermediate.⁶

(11) Approximate homolytic C–H bond dissociation energies (kcal/mol) are as follows: primary, 98; secondary, 94.5; tertiary, 91; $PhCH_2-H$, 85; see: Solomons, T. W. G. *Organic Chemistry*, 5th ed.; John Wiley & Sons: New York, 1992, p 266.

(12) Ceccherelli, P.; Curini, M.; Marcotullio, M. C.; Mylari, B. L.; Wenkert, E. *J. Org. Chem.* **1986**, 51, 1505. (b) Sejbál, J.; Klimot, J.; Vystřcil, A. *Coll. Czech. Chem. Commun.* **1988**, 53, 118.

(13) (a) Jefford, C. W.; Velarde, J. A.; Bernardinelli, G.; Bray, D. H.; Warhurst, D. C.; Milhous, W. K. *Helv. Chim. Acta* **1993**, 76, 2775. (b) Posner, G. H.; Oh, C. H.; Gerena, L.; Milhous, W. K. *Heteroat. Chem.* **1995**, 6, 105.

(14) Pyle, S. J.; Amarant, V.; Graham, D. G.; Anthony, D. C. *J. Neuropathol. Exp. Neurol.* **1992**, 51, 451. See also: Fishwick, J.; McLean, W. G.; Edwards, G.; Ward, S. A. *Chem.-Biol. Interact.* **1995**, 96, 263.

(15) (a) Yang, Y.-Z.; Asawamahesakda, W.; Meshnick, S. R. *Biochem. Pharmacol.* **1993**, 46, 336. (b) Asawamahesakda, W.; Benakis, A.; Meshnick, S. R. *J. Lab. Clin. Med.* **1994**, 123, 757. (c) Asawamahesakda, W.; Ittarat, I.; Pu, Y.-M.; Ziffer, H.; Meshnick, S. R. *Antimicrob. Agents Chemother.* **1994**, 38, 1854.

(16) A peroxidic 1,6-dicarbonyl compound has been reported to have antimalarial activity: Baker, J. T.; McChesney, J. D.; Chi, H. T. *Pharm. Res.* **1993**, 10, 662.

(17) For some recent studies, see: (a) Dexter, A. F.; Hager, L. P. *J. Am. Chem. Soc.* **1995**, 117, 817. (b) Minisci, F.; Fontant, F.; Araneo, S.; Recupero, F.; Banfi, S.; Quici, S. *J. Am. Chem. Soc.* **1995**, 117, 226. (c) Tian, Z.-Q.; Richards, J. L.; Traylor, T. G. *J. Am. Chem. Soc.* **1995**, 117, 21.

(18) Posner, G. H.; Wang, D.; González, L.; Tao X.; Cumming, J. N.; Klinedinst, D.; Shapiro, T. A. *Tetrahedron Lett.* **1996**, 37, 815. We have recently found 1,3-dibenzoylpropane (the 1,5-diketone **9** in this reference) to have some (albeit low) antimalarial activity.

(19) For a recent ionic mechanism discussion of artemisinin activation by non-heme iron, see: Haynes, R. K.; Vonwiller, S. C. *Tetrahedron Lett.* **1996**, 37, 257.